Tag: Clinical Trials

Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial – their approval does not mean that the therapy is ‘safe’ or effective, only that the trial may be conducted.

Swiss biopharmaceutical company launched new clinical trials website

Debiopharm International, Swiss-based global biopharmaceutical company, announced today the launch of its new clinical trials website

British company developed a solution for antimicrobial resistance problem

microbiology plates
Helperby Therapeutics have developed a novel answer to the clear and present danger of antimicrobial resistance - Antibiotic Resistance Breakers

EMA gave approval to Roche’s multiple sclerosis drug

The European Medicines Agency has recommended granting a marketing authorisation for Ocrevus for the treatment of patients with relapsing multiple sclerosis

Boehringer Ingelheim and CellSight Technologies announced collaboration

CellSight Technologies, a US-based PET imaging company, announced a collaboration with Boehringer Ingelheim to evaluate PET imaging tracer

Takeda and Portal Instruments develop needle-free drug delivery device

Takeda Pharmaceutical Company and Portal Instruments today announced a collaboration to develop and commercialize needle-free drug delivery device

Bayer and Compugen established a process development and service agreement

Compugen Ltd., has advanced COM902, its lead anti-TIGIT antibody, into manufacturing for an investigational new drug application anticipated in 2019

Oxford BioDynamics will collaborate with major US biopharma company

Oxford BioDynamics announced that it has entered into an initial collaboration with a major US biopharmaceutical company

Sumitomo Dainippon Pharma and Poxel will jointly develop diabetes drug

diabetes drugs
Sumitomo Dainippon Pharma and POXEL SA announced the signing of a strategic partnership for the development and commercialization of an investigational therapeutic agent for type 2 diabetes

Bristol-Myers Squibb joined ORIEN Avatar Research Program

M2Gen announced that Bristol-Myers Squibb Company has joined the Oncology Research Information Exchange Network® Avatar Research Program

The Human Vaccines Project strives to gear up influenza vaccine development

influenza vaccine
The Human Vaccines Project, a public-private partnership, announced the launch of the Universal Influenza Vaccine Initiative

FDA aknowledged hemophilia gene therapy as Breakthrough Designation

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration granted valoctocogene roxaparvovec Breakthrough Therapy Designation

Chumakov Scientific Center starts clinical trials of inactivated polio vaccine

Chumakov Federal Scientific Center submitted to the Russian Ministry of Health an application for clinical trials of the first Russian inactivated polio vaccine

Alopexx accomplished Phase I of broad-spectrum anti-microbial vaccine

Alopexx Vaccine LLC announced that it has completed a Phase 1 clinical trial with AV0328, a vaccine targeting the broadly expressed microbial antigen

SGS and Bavarian Nordic will cooperate to develop RSV vaccine

SGS announced that it has entered into collaboration with Bavarian Nordic A/S to develop a new respiratory syncytial virus (RSV) challenge strain

Nacimbio completes trials of pentavaccine with acellular pertussis component

National Immunobiological Company (Nacimbio) completed the clinical trials of the first Russian combined 5-component vaccine with acellular pertussis component

AbbVie and Turnstone Biologics starts cooperation on viral immunotherapies

abbvie office
AbbVie and Turnstone Biologics announced a research, option and license agreement whereby AbbVie obtained an option to license up to three of Turnstone's next viral immunotherapies